Direct and Indirect Economic Impact of RDL 16/2012 on the Pharmacy. Report



Description


This report primarily focuses on the direct and indirect implications of RD 16/2012 on the pharmacy.

This report has the objective:

  • Review the impact of past and recent measures of healthcare costs.
  • Analysis of direct and indirect measures of  RD 16/2012 in the OF, such as: Introduction of the concept “lowest price”, new model of user input, scale of deductions, and possible de-funding of drugs.
  • Conclusions and reflections


Authors


Antares Consulting; Rafael Borrás



An Open-Innovation Test Bed for Medical Devices: Kick-off for new EU Research Project TBMED

13 European partners aim to accelerate patient access to innovative solutions

News  February 26, 2019
Copyright © 2010 Antares Consulting S.A. All rights reserved   |   Terms of use   |   Privacy Police